In addition, AML development was driven by the branching evolution of the TET2N191Kfs*4/RUNX1R201Q_HOM clone through the acquisition of two independent mutations in the NRAS and KIT genes, with the emergence of two independent new subclones (C6 and C7, respectively). Here, NRAS is linked to acute myeloid leukemia.